Skip to main content
Clinical Trials/ISRCTN17778965
ISRCTN17778965
Active, not recruiting
未知

A randomised, controlled, multi-centre clinical study to evaluate the outcomes following the intra-operative use of the LightPathTM Imaging System compared to standard practice in wide local excision (WLE) for breast cancer

ightpoint Medical Ltd0 sites66 target enrollmentFebruary 11, 2016

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
ightpoint Medical Ltd
Enrollment
66
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33738563/ pilot study results (added 22/03/2021)

Registry
who.int
Start Date
February 11, 2016
End Date
December 31, 2022
Last Updated
3 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
ightpoint Medical Ltd

Eligibility Criteria

Inclusion Criteria

  • 1\. Signed an informed consent form prior to any study related activity
  • 2\. Able to give voluntary, written informed consent to participate in this study.
  • 3\. Able to understand this study and are willing to complete all the study assessments
  • 4\. Female subjects \=18 years of age with a diagnosis of invasive breast cancer or DCIS
  • 5\. Those who have unifocal disease in one quadrant of the breast, not including the nipple
  • 6\. Those who have a tumour diameter of at least 10 mm (if measurable by mammography)
  • 7\. Scheduled for WLE \+/\- SLNB or ALND
  • 8\. Of childbearing age must have a negative pregnancy test (by Beta HCG qualitative analysis), or must have had a history of a surgical sterilisation, or must give history of no menses in the past twelve months

Exclusion Criteria

  • Subjects who:
  • 1\. Have had surgery in the operated breast in the past 2 years
  • 2\. Have had radiotherapy in the operated breast
  • 3\. Have had neoadjuvant systemic therapy
  • 4\. Have had systemic chemotherapy in the past two years
  • 5\. Not suitable for WLE
  • 6\. Have blood glucose level \=12 mmol/L
  • 7\. Have known hypersensitivity to 18F\-FDG
  • 8\. Planned perioperative or Intraoperative Radiation Therapy (IORT) or brachytherapy
  • 9\. Pregnant or lactating

Outcomes

Primary Outcomes

Not specified

Similar Trials